Oxford Biomedica Share News (OXB)
OXB Share
OXB Share
OXB Share
OXB Share
OXB
OXB Share
OXB Level 2
OXB Live
OXB Broker
OXB Directors
OXB Financial
OXB
OXB Short
OXB
Last checked at -
(Sharecast News) - Gene and cell therapy company Oxford Biomedica has joined a consortium led by the Jenner Institute at Oxford University, it announced on Wednesday, to rapidly develop, scale-up and manufacture a potential vaccine candidate for Covid-19, called 'ChAdOx1 nCov-19'.
Read more
UK TRADING UPDATE SUMMARY: Novacyt Gets WHO Covid-19 Test Kit Okay
Read moreDIRECTOR DEALINGS SUMMARY: Plus500 Team Spend GBP14 Million On Shares
Read moreOxford Biomedica Expects 2019 Loss As Chair Steps Down, Signs New Deal
Read moreOxford Biomedica Sells USD8.4 Million In Orchard Therapeutics Shares
Read moreOxford Biomedica Extends Agreement With Novartis By Five Years
Read moreBROKER RATINGS SUMMARY: Barclays Cuts Whitbread And Raises SSE
Read more(Sharecast News) - Gene and cell therapy company Oxford Biomedica announced on Tuesday that Novo Holdings has agreed to invest up to £53.5m in the group, in return for new ordinary shares representing up to 10.1% of the outstanding shares after the capital increase.
Read more(Sharecast News) - Bakkavor Group: Berenberg downgrades to sell with a target price of 105p.
Read more(Sharecast News) - Gene and cell therapy group Oxford Biomedica reported a 72% increase in gross income in its preliminary results for the year ended 31 December on Thursday, to £67.9m.
Read more(Sharecast News) - Gene and cell therapy company Oxford Biomedica has entered into a research and development collaboration with Microsoft Research, it announced on Tuesday, to improve the yield and quality of next-generation gene therapy vectors using the cloud and machine learning.
Read more(Sharecast News) - Gene and cell therapy group Oxford BioMedica announced the formation of a new digital framework initiative on Friday, which it said would streamline the production of next-generation medicines.
Read more(Sharecast News) - Gene and cell therapy group Oxford BioMedica noted on Thursday that its partner, Axovant Sciences - a company developing innovative gene therapies for neurologic and neuromuscular diseases - has announced the successful dosing of the first patient in a clinical study of AXO-Lenti-PD, also known as OXB-102.
Read more(Sharecast News) - Biopharmaceutical company Oxford Biomedica saw its shares rise on Thursday after its first half gross income more than doubled due to two huge contracts.
Read moreWednesday 23 MayBovis Homes GroupSt James's Place Keller GroupGamma Emerging
Read more
Last checked at